The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
Ami Organics recently announced contract with global MNC for manufacturing of electrolyte for battery cells
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
European operations' revenue grew 58.4% to Rs 599.7 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Subscribe To Our Newsletter & Stay Updated
